AR and prostate carcinoma: Among the mSWI/SNF complexcomponents, only ATPases and bromodomain containing 9 (BRD9) were found to bedirectly targetable by recently developed PROTAC degraders, which have beenengineered to induce target protein degradation through the ubiquitin-proteasomesystem (Figure S1B,TableS1).27,28 Our team recently showcasedthe promising anti-tumor efficacy of the PROTAC degrader targeting the mSWI/SNFATPase subunit in preclinical models of AR-driven prostate cancer.23 Here, we evaluated theefficacy of this mSWI/SNF ATPase PROTAC degrader, AU-15330, across a spectrum ofSCLC cell lines.